Highlights NeuroMetrix, Inc.

Equities

NURO

US6412558800

Market Closed - Nasdaq Other stock markets 02:00:00 10/05/2024 am IST			5-day change	1st Jan Change
4.41 ^USD	-0.37%		-1.34%	+22.50%

19/04	Sector Update: Health Care Stocks Advance Late Afternoon	MT
19/04	Sector Update: Health Care Stocks Rise Friday Afternoon	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Advance Late Afternoon	20/04	MT
Sector Update: Health Care Stocks Rise Friday Afternoon	19/04	MT
NeuroMetrix, Inc. Announces Publication of Study Demonstrating That DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy	14/03	CI
NeuroMetrix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22/02	CI
NeuroMetrix, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	22/02	CI
Neurometrix, Inc. Reports Encouraging Results from Pilot Clinical Trial of Quell®? in Post-Acute Covid-19 Syndrome (Long Covid)	12/12	CI
NeuroMetrix, Inc. Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Showing that Quell Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy	05/12	CI
Reverse Split: 1 of 8	22/11	FA
NeuroMetrix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	26/23/26	CI
NeuroMetrix, Inc. and the National Fibromyalgia Association to Collaborate to Improve the Quality of Life for People Living with Fibromyalgia	02/23/02	CI
NeuroMetrix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	27/23/27	CI
NeuroMetrix, Inc. Announces Sales Force Expansion for Quell Fibromyalgia	11/23/11	CI
NeuroMetrix, Inc. Announces Presentation of New Clinical Data At the Diabetes UK Meeting	07/23/07	CI
NeuroMetrix, Inc. Demonstrates Encouraging Clinical Trial Results in Chemotherapy Induced Peripheral Neuropathy	31/23/31	CI
NeuroMetrix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	03/23/03	CI
NeuroMetrix, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23/23/23	CI
Earnings Flash (NURO) NEUROMETRIX Posts Q4 Revenue $1.8M	23/23/23	MT
NeuroMetrix, Inc. Announces Launch of DPNCheck 2.0, Its Fast, Accurate, Quantitative Screening Test for Peripheral Neuropathy	23/23/23	CI
NeuroMetrix, Inc. to Introduce Quell Fibromyalgia At the American College of Rheumatology 2022 Annual Meeting	08/22/08	CI
NeuroMetrix, Inc. Announces Strategic Launch of Quell Fibromyalgia	03/22/03	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights NeuroMetrix, Inc.

Equities

NURO

US6412558800

Highlights

Filters